Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 cardiovascular outcomes study of fasiglifam added to standard of care in type 2 diabetes
2011-001732-37Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Fasiglifam + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first primary cardiovascular composite event. Started Jul 2012; status: terminated.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001732-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001732-37.